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Diseases caused by single-gene mutations can
display substantial phenotypic variability, which
may be due to genetic, environmental, or epigenetic
modifiers. Here, we induce Gaucher disease (GD), a
rare inherited metabolic disorder, by injecting 15
inbred mouse strains with a low dose of a chemical
inhibitor of acid b-glucosidase, the enzyme defective
in GD. Different mouse strains exhibit widely different
lifespans, which is unrelated to levels of acid b-glu-
cosidase’s substrate accumulation. Genome-wide
association reveals a number of candidate risk loci,
including a marker within Grin2b, which in combina-
tion with another marker allows us to predict the life-
span of additional mouse strains. An antagonist of
the NMDA receptor (encoded by Grin2b) significantly
increases the lifespan of GD mice that would other-
wise have lived for a short time. Our data identify
putative modifier genes that may be involved in
determining GD severity, which might help elucidate
phenotypic variability between patients with similar
GD mutations.
INTRODUCTION
Monogenic diseases frequently present with a wide spectrum of
disease symptoms such that genotype-phenotype correlations
are often poor and identical mutations may trigger diverse phe-
notypes (Argmann et al., 2016). A classic example is Gaucher
disease (GD), a rare lysosomal storage disorder (LSD) caused
by mutations in the GBA1 gene, in which some patients display
systemic disease with little or no neurological involvement while
others display an aggressive neurological disease (nGD) (Gra-
bowski et al., 2013). Moreover, heterozygous and homozygous
mutations in GBA1 are the highest known genetic risk factor2546 Cell Reports 16, 2546–2553, September 6, 2016 ª 2016 The Au
This is an open access article under the CC BY-NC-ND license (http://for the development of Parkinson’s disease (PD) and dementia
with Lewy bodies (DLB) (Schiffmann and Vellodi, 2007; Nalls
et al., 2013). Thus, it is becoming clear that the one gene/one
disease paradigm needs re-evaluating (Gropman and Adams,
2007).
The typical way to study genetic modifiers of disease are link-
age and association studies, although large multi-scale omic
technologies and network approaches might provide an alterna-
tive approach (Argmann et al., 2016). In this study, we took
advantage of the availability of conduritol b-epoxide (CBE), an in-
hibitor of acid b-glucosidase (GCase), the enzyme defective in
GD. CBE has been widely used to induce GD in mice (Farfel-
Becker et al., 2011a; Vardi et al., 2016), but most studies use
high amounts of CBE, which can lead to rapid death and there-
fore mask phenotypic variability. We used a lower dose of CBE
and injected 15 inbred mouse strains from diverse phylogenetic
origins whose SNP profiles are available. A genome-wide asso-
ciation study (GWAS) identified putative modifier genes, allowed
prediction of phenotypic variability in additional mouse strains,
and suggested a possible therapeutic target for nGD. We sug-
gest that this approach could be used for studying phenotypic
variability in other inborn errors of metabolism.
RESULTS
Phenotypic Variability of Inbred Mouse Strains upon
CBE Injection
Genetic background influences the severity of LSDs in mice,
although typically such studies are performed using only two
or three mouse strains (Kova´cs and Pearce, 2015; Parra et al.,
2011). We tested phenotypic variability in 15 inbred mouse
strains that have each undergone >20 generations of inbreeding,
are from diverse phylogenetic origins (Figure 1A), and for whom
SNP profiles (Kirby et al., 2010) are available (http://phenome.
jax.org). Male mice were injected daily with 25 mg CBE/kg
body weight starting at post-natal day 8. A substantial difference
in lifespan was observed (Figure 1B), with some strains
dying by 50 days of age (A/J, AKR/J, C3H/HeJ, DBA/2J,thor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Variation in Lifespan among
Mouse Strains upon CBE Injection
(A) Phylogenetic tree of 94 inbred mouse strains
(adapted from Kirby et al., 2010, with permission
from the Genetics Society of America). The 15
mouse strains used in this study are highlighted
in color.
(B) Each mouse strain was injected daily i.p. with
25 mg CBE/kg body weight from post-natal day
(P)8. Mouse survival is shown as a Kaplan-Meier
survival plot and is color-coded as in (A) (n = 4–9
per mouse strain). Note that there was no corre-
lation between lifespan and the initial weight of the
mice on P8 (r2 = 0.074) nor between the lifespan of
untreated mouse strains (Yuan et al., 2009) and
lifespan upon CBE treatment (r2 = 0.007).
(C) Motor coordination was determined by the
hanging wire test. Mice injected with PBS, black
circles; mice injected with CBE, colored circles
(color coded as in A). Results are means ± SEM
(n = 4–5 per strain, *p < 0.05).
(D) CD68 immunofluorescence in layer V of the
cortex. The age (days) at which the analysis was
performed is shown in italics.
(E) GCase activity and GlcCer and GlcSph levels in
mice injected daily with PBS (black bars) or with
CBE (red bars) from P8–18. Values are means ±
SEM (n = 2 for analyses performed in duplicate).
The inset shows the lack of correlation (r2) between
the lifespan of the mice and the extent of CBE
inhibition or levels of GlcCer and GlcSph accu-
mulation upon CBE injection.C57BL/6JOlaHsd, MRL/MpJ, WSB/EiJ, and MOLF/Ei; short-
lived strains) while others lived for 80–200 days (NZW/
LacJ, FVB/NJ, 129S1/SvImJ, PWD/PhJ, BALB/cJ, KK/HiJ, and
BTBR T+ Itpr3tf/J; long-lived strains). Strains with a short lifespan
had pronounced motor defects (Figures 1C and S1), whereas
those with a longer lifespan developed motor abnormalities at
a later age (Figure 1C). Moreover, mice that lived for a short
time displayed activated microglia in layer V of the cortex, an
area that shows significant pathology in mouse models of nGD
(Farfel-Becker et al., 2011b; Vitner et al., 2014). Few, if any, acti-
vated microglia were detected in the same region in long-lived
strains, even at later stages of the disease (Figure 1D), suggest-
ing that mice with a long lifespan may die from non-neurological
disease.
Although basal GCase activity varied somewhat among
different strains, the extent of GCase inhibition in the brain by
CBE was 90%–95% in all strains, and there was no correlationCell Reporbetween lifespan and basal GCase activity
(r2 = 0.13) or the extent of inhibition byCBE
(r2 = 0.06) (Figure 1E). We also determined
levels of the two sphingolipid substrates
that accumulate in GD, glucosylcera-
mide (GlcCer) and glucosylsphingosine
(GlcSph). Differences in lipid levels were
apparent between strains, but no correla-
tionwas found between lifespan and basal
GlcCer (r2 = 0.14) orGlcSph (r2 = 0.07) levelor with increasedGlcCer/GlcSph levels upon CBE treatment (Fig-
ure 1E); furthermore, there was no correlation between levels of
twoother sphingolipids, galactosylceramide (r2 = 0.01) andgalac-
tosylsphingosine (r2=0.01), and lifespan (FigureS2). These results
demonstrate that lipid accumulation is necessary, but not suffi-
cient, to trigger neurological disease in nGD, and they exclude
the possibility of differential metabolismofCBE in differentmouse
strains. Moreover, there is no correlation between the life expec-
tancies of untreated mouse strains (http://phenome.jax.org)
(Yuan et al., 2009) and lifespan after CBE injection. This demon-
strates an unexpected level of phenotypic variability between
mouse strains upon CBE injection, implying a role for genetic
modifiers as determinants of GD severity.
Identification of Putative Genetic Modifiers
We performed a GWAS using the efficient mixed-model associ-
ation (EMMA) algorithm, which corrects for population structurets 16, 2546–2553, September 6, 2016 2547
Figure 2. Identification of Putative Modifier
Genes by GWAS
(A) Manhattan plot showing thelog10 of the odds
of association of the markers in each chromo-
some. The threshold of significance is indicated
(red line) as are the suggestive threshold (blue line)
and the top associated genes.
(B) Strains organized according to average lifespan
and the genotypes of the peak-associated SNPs
per gene. Note that the PWD/PhJ strain appears to
be an outlier since it displayed a different pattern of
distribution of the genotypes among the long-lived
strains, perhaps due to its wild-derived origin
(Kirby et al., 2010). Adenine (A), magenta; cytosine
(C), blue; guanine (G), green; thymine (T), yellow;
Chr, chromosome. Further details about the func-
tions of these genes and the diseases with which
they are associated are given in Table S2.and cofounding effects (Kang et al., 2008), based on the life-
spans of the mouse strains upon CBE injection. The genome-
wide Bonferroni threshold of significance was 1.25 3 108,
and suggestive associations were considered from p = 4.1 3
106 (Kang et al., 2008) (Figure 2A). We analyzed SNPs residing
within genes and identified 17 genes. All of the identified SNPs
were located in introns (with the exception of rs27731485, which
was located at the 30 UTR region of Plekhf2). Mouse strains were
organized by lifespan and a matrix was plotted using the geno-
types of the SNPs (Figure 2B). Short-lived strains showed a
pattern of distribution of genotypes that differed from long-lived
strains, and strains with intermediate lifespans displayed inter-
mediate patterns.
To test whether a combination of markers could predict
the severity of nGD, we analyzed the SNP profiles of other
mouse strains. No additional strains shared the distribution of
genotypes as the short-lived strains (i.e., A/J, AKR/J, and C3H/
HeJ) or the long-lived strains (i.e., BALB/cJ, KK/HiJ, and
BTBRT+ Itpr3tf/J).Weconsequently analyzed the genomic regions
where the SNPs reside, by downloading the genomic data (http://
www.sanger.ac.uk/science/data/mouse-genomes-project) avail-
able for the strains used in our study, to determine the best candi-
dates for predicting lifespan.Wechose rs32982614,which resides
within Ctnnd2, and rs29869040, which resides in Grin2b, as they2548 Cell Reports 16, 2546–2553, September 6, 2016delineate between short- and long-lived
strains. BPL/1J and I/LnJ mouse strains
shared the genotypes of the short-lived
strains (Figure 3A), and P/J and BPN/3J
shared the genotypes of the long-lived
strains for these SNPs (Figure 3A). We in-
jected these mice (Figure 3B) with CBE,
andour predictionswith respect to lifespan
were validated (Figure 3C). Finally, we per-
formed an additional GWAS using mouse
strains that lived for >80 days, since they
displayed significant variation in lifespan.
Additional SNPs were found in Mgat5,
Aff2, and Tox3, and in two uncharacterized
genes (Figure S3; Table S3).To discover genes involved in the susceptibility or resistance
to develop neurological disease, we performed microarray anal-
ysis in cortex, one of themost significantly affected brain areas in
nGD (Farfel-Becker et al., 2011b), in short-lived (C57BL/6JO-
laHsd and C3H/HeJ) and long-lived (FVB/NJ and 129S1/SvImJ)
strains in PBS- and CBE-treated mice (n = 3 per condition).
On day 18, 161 genes displayed differential expression between
short- and long-lived strains (>1.5-fold change, corrected
p < 0.05) upon PBS injection, while 228 genes differed in mice
injected with CBE (Table S3). Importantly, of these, 116 were
common (Figure 3D) irrespective of whether they were treated
with PBS or CBE. Most of the 116 genes have unknown func-
tions, but 24 are genes for non-coding RNAs, including long
non-coding RNAs, pseudogenes, andmicroRNAs. Domain anal-
ysis (Figure 3E) revealed that the takusan family was highly
enriched in these 116 genes (p = 1.337), and members were ex-
pressed at lower levels in the short- versus long-lived strains
(Figure 3F), a finding validated by qPCR using primers flanking
the 2610042L04Rik gene in two short-lived (A/J and C57BL/
6JOlaHsd) and two long-lived (FVB/NJ and NZW/LacJ) strains
(Figure 3G). The takusan family is involved in the interaction of
postsynaptic molecules with both NMDA and AMPA glutamate
receptors (Tu et al., 2007), suggesting a fundamental difference
in synaptic function between short- and long-lived strains.
Figure 3. Predictive Value of a Combination
of SNPs
(A) Genotypes of the predicted short- and long-
lived mouse strains are shown.
(B) Phylogenetic tree highlights the four additional
strains used to predict lifespan.
(C) Kaplan-Meier survival curves of strains injected
daily with CBE starting at P8. Mouse strains are
color coded as in (A) (n = 3–5).
(D) Venn diagram shows differentially regulated
genes between short- and long-lived strains.
(E) Classification of differentially regulated genes in
short- versus long-lived strains. PFAM domains
(Finn et al., 2016), which are found in at in least
three proteins, as well as the non-coding genes are
shown. Details can be found in Table S4.
(F) Heatmap shows differential expression of the
takusan family genes.
(G) qPCR of 2610042L04Rik in cortical homoge-
nates from 18-day-old PBS- and CBE-treated A/J,
C57BL6/JOlaHsd (C57), FVB/NJ (FVB), and NZW/
LacJ (NZW) mice. Results are means ± SEM (n = 3
per condition, ***p < 0.001 between short- and
long-lived strains).Role of NR2B in nGD
A number of the genes identified by GWAS are involved in the
regulation of glutamate-related pathways in the brain, including
Adk,Ctnnd2,Grik2, andGrin2b (Table S2), consistent with earlier
studies suggesting a role for glutamate in nGD pathology (Korko-
tian et al., 1999; Pelled et al., 2005). Grin2b encodes for NR2B,
the B subunit of the NMDA glutamate receptor. Analysis of
Grin2b mRNA levels in cortex demonstrated upregulation in
the short-lived strains (p < 0.05) (Figure 4A). Treatment of A/J,
C57BL/6JOlaHsd, C3H/HeJ, and DBA/2J strains with meman-
tine, an FDA-approved NMDA antagonist for use in moderate-
to-severe Alzheimer’s disease (Aarsland et al., 2009; Howard
et al., 2012), and CBE significantly increased their lifespan
compared to mice treated with CBE alone (Figure 4B), whereas
activation of the NMDA receptor by D-cycloserine (D-Ser) (Da-
nysz and Parsons, 1998) decreased the lifespan of BALB/cJ
mice (Figure 4C) and that of three other long-lived strains
(129S1/SvImJ, FVB/NJ, and BTBR T+ Itpr3tf/J; data not shown).
Upon memantine treatment, we observed a reduction in the
rate of weight loss (Figure 4D), a delay in appearance and pro-Cell Reporgression of motor symptoms (Figure 4E),
and a delay in appearance of activated
microglia (Figure 4F). Moreover, two
proteins recently implicated in nGD path-
ogenesis, the cleaved form of receptor-in-
teracting protein kinase 1 (RipK1) (Vitner
et al., 2014) and double-stranded RNA
(dsRNA)-activated protein kinase (PKR)
(Vitner et al., 2016), were significantly
reduced (Figure 4G), suggesting that acti-
vation of the RipK pathway in GD may
occur downstream of NR2B. The unlikely
possibility that memantine affects the effi-
cacy of GCase inhibition by CBE wasexcluded by demonstrating that GCase was inhibited to a similar
extent with or without memantine (Figure 4H). The lifespan of
Gbaflox/flox;nestin-Cre mice, which display severe neurological
symptoms and die at 3 weeks of age (Farfel-Becker et al.,
2011b), also was extended to a small but significant extent
(p < 0.001) using a higher dose of memantine (Figure 4I).
Finally, we examined levels of NR2B in post-mortem human
brain tissue obtained from type 1 (systemic disease, no neuro-
logical symptoms), type 2 (severe, acute neurological disease,
infantile death), and type 3 GD (chronic neurological disease,
juvenile death) (Pelled et al., 2005). NR2B levels were highest
in the two available type 2 GD human brains (Figure 4J). We sug-
gest that Grin2bmodulation might be able to modify the severity
of GD pathology and is a potential therapeutic target.
DISCUSSION
The genetic diversity of inbred mouse strains previously has
been exploited to uncover genes involved in metabolic and toxi-
cological traits and in viral infections and others (Crowley et al.,ts 16, 2546–2553, September 6, 2016 2549
Figure 4. Antagonism of NR2B Improves
Neurological Symptoms in GD Mice
(A) qPCR of Grin2b in cortical homogenates from
18-day-old PBS- and CBE-treated A/J, C57BL6/
JOlaHsd (C57), FVB/NJ (FVB), and NZW/LacJ
(NZW) mice. Results are shown as fold change of
the means ± SEM (n = 3 per condition, *p < 0.05).
(B) Average survival times of mouse strains in-
jected daily with CBE (red bars) or CBE + mem-
antine (3 mg/kg) (blue bars) starting on P8. Values
are means ± SD (A/J, n = 10; DBA, n = 5–10; C3H/
HeJ (C3H), n = 3–7; C57BL6/JOlaHsd (C57),
n = 3–9; *p < 0.05).
(C) Average survival times of BALB/cJ mice in-
jected daily with CBE ± D-Ser or PBS + D-Ser. The
PBS + D-Ser mice were sacrificed at P180. Values
are means ± SD (CBE, n = 5; CBE + D-Ser, n = 6;
PBS + D-Ser, n = 3; *p < 0.05 compared to CBE).
(D) Body weight of A/J mice injected daily with CBE
(red) ± memantine (blue) is shown (n = 10).
(E) Motor coordination determined by the hanging
wire test in AJ mice treated with PBS (black), CBE
(red), or CBE ± memantine (blue) as in (A). Values
are means ± SEM (n = 4–5, *p < 0.05).
(F) Western blot of Mac2 in homogenates (75 mg
protein) from brains of C57BL6/JOlaHsd mice
treated as indicated at P30. Quantification is
means ± SD (n = 3). M, memantine.
(G) PKR and Rip1 levels in homogenates (75 mg
protein) from the brains of C57 mice treated as
indicated at P30 are shown.
(H) GCase activity measured on the indicated days
(P) of A/J mice injected daily with PBS, CBE, or
CBE + memantine (3 mg/kg). Values are means ±
SD (n = 2 in duplicate, *p < 0.001).
(I) Kaplan-Meier survival curves of Gbaflox/flox;
nestin-Cre mice injected daily with PBS (n = 9) or
30mg/kg body weight memantine (n = 6, p < 0.001)
are shown.
(J) Western blots of NR2B in samples (90 mg pro-
tein) of human GD brain, with quantification. The
genotypes of the samples from left to right are
as follows: type 1, N370S/c.208delC and N370S/
N370S; type 2, IVS2 + 1GNA/F251L and IVS2 +
1GNA/L444P; and type 3, D409H/L444P + Dup
and G377S/g.5245delT (Pelled et al., 2005)
(*p < 0.05).2012; Parks et al., 2013; Rasmussen et al., 2014). However, the
current study uses this approach to uncover modifier genes in
a mouse model of a monogenic disease, and, in principle, this
could be used for other inbred errors of metabolism, provided
that suitable methods are available to induce disease. In this
respect, GD is prototypical since it can be easily and rapidly
induced by CBE in a time- and dose-dependent manner (Vardi
et al., 2016).
Ours is not the first attempt to discover modifier genes for GD.
For instance, SCARB2 was suggested as a risk factor for devel-
oping an epileptic phenotype in type 3 GD (Velayati et al., 2011),
and other studies have implicated glucosylceramide synthase,
GBA2, GBA3, vitamin D receptor, IL-6, and TNF-a as possible
modifiers,butnoconsistentcorrelationwasobservedwithdisease
severity (Beutler andWest, 2002;Altarescuet al., 2003, 2005;Dek-
ker et al., 2011; Greenwood et al., 2010). GWAS also was per-2550 Cell Reports 16, 2546–2553, September 6, 2016formed in a cohort of Jewish patients homozygous for the
N370S mutation, and the results suggested CLN8 as a candidate
modifier gene for type 1 GD, although genome-wide significance
was not met after Bonferroni corrections (Zhang et al., 2012).
No significant associations in loci encoding for genes related
to sphingolipid metabolism or in genes associated with aging
and/or longevity (i.e., Apoe1, Foxo3A, and Igf1) (Peters et al.,
2015) were detected. Genes with the highest significance in
our GWAS, i.e.,Adk,Dpp10,Ctnnd2, andGrin2b, are all involved
in pathways related to neuronal excitability. Others such as
Plekhf2 and Atp6v1b2 play critical roles in endolysosomal
biology, and Fat4 andNf2 are critical for brain development, sug-
gesting that aspects of electrophysiology, neurodevelopment,
and endolysosomal function may determine whether mice
develop nGD, a notion supported by the potential role of the
takusan family.
Additional information can be derived from our study on the
role of specific genes in nGD pathogenesis. First, the C57BL/
6JOlaHsd strain that we used does not express a-synuclein
(Specht and Schoepfer, 2001), and the C3H/HeJ strain has
an inactivating mutation in Toll-like receptor 4 (Poltorak et al.,
1998); since both of these mice had a short lifespan, we can
conclude that these proteins may be dispensable for develop-
ment of the most aggressive forms of nGD. Second, evaluation
of autistic-like behavior (Moy et al., 2007) in nine of the same
inbred mouse strains used in our study demonstrated that
most mouse strains that have short lifespans showed higher
social behaviors, while most long-lived strains presented with
autistic-like behavior. Autism spectrum disorders are hypoglu-
tamatergic disorders (Vahabzadeh et al., 2015) that can be
caused by loss of function in GRIN2B (Pan et al., 2015), consis-
tent with the notion that alterations in NR2B might contribute
to the susceptibility and resistance to developing autism and
possibly to the development of mild versus aggressive forms
of GD.
One of the most noteworthy findings from our study is the
possible use of memantine as a therapy for nGD. Whether mem-
antine could be used as a therapeutic option in human nGD pa-
tients remains to be established, as does the possibility that
SNPs or mutations in the same genes discovered in our mouse
GWAS might be predictive for the development of neurological
symptoms in human GD patients. Although some mutations in
the human GBA1 gene predispose toward neurological disease
(i.e., L444P) (Grabowski et al., 2013), it is essentially impossible
to predict the course of disease development for most GD pa-
tients, particularly for compound heterozygotes. Whether the
genes identified in our study might lead to such predictions
and whether any of the genes might lead to unraveling the
elusive connection between GD and PD and LSD remain to
be established.
EXPERIMENTAL PROCEDURES
GD Mouse Models
Pure inbred mouse strains (BTBR T+ Itpr3tf/J, C3H/HeJ, DBA/2J, MRL/MpJ,
WSB/EiJ, MOLF/Ei, PWD/PhJ, KK/HiJ, BPL/1J, I/LnJ, BPN/3J, and LP/J)
were from Jackson Laboratory, Harlan UK (A/J, AKR/J, NZW/LacJ, and
129S1/SvImJ), and Harlan (C57BL/6JOlaHsd, BALB/cJ, and FVB/NJ). Male
mice were injected daily intraperitoneally (i.p.) with 25 mg/kg body weight
CBE (Calbiochem Millipore) with or without memantine (Sigma-Aldrich)
(3 mg/kg body weight/day) or with D-Ser (Sigma-Aldrich) (200 mg/kg/day),
starting from post-natal day 8 (Vitner et al., 2014). Motor coordination was
evaluated weekly by the hanging wire test (Alvarez et al., 2008) as documented
in the Supplemental Experimental Procedures. Gbaflox/flox;nestin-Cre mice
(Enquist et al., 2007; Farfel-Becker et al., 2011b) were injected daily i.p. with
30 mg memantine/kg body weight from P8. Mice were maintained under spe-
cific pathogen-free conditions in the Experimental Animal Center of the Weiz-
mann Institute of Science, and they were handled according to protocols
approved by the Weizmann Institute Animal Care Committee according to
international guidelines.
Immunofluorescence
Free-floating coronal brain sections (40 mm) were blocked for 1 hr with
2% BSA/0.2% Triton X-100 in PBS and incubated overnight with a rat
anti-CD68 antibody (1:1,000; Serotec). CD68 was detected using a Cy3-
conjugated donkey anti-rat antibody (1:200; Jackson ImmunoResearch
Laboratories).GCase Activity Assay and Sphingolipid Analysis
GCase activity and sphingolipid analysis were measured as described (Farfel-
Becker et al., 2014). Additional details can be found in the Supplemental
Experimental Procedures.
GWAS
GWA mapping was performed, using the lifespan of the inbred mouse strains
injected with CBE, by EMMA using individual SNP associations (Kang et al.,
2008). EMMA corrects for genetic relatedness and population structure, mini-
mizing false associations. To assure high-resolution mapping of the mouse
genome, the association was performed using 4,000,000 SNPs per strain.
The SNP profiles of each strain were downloaded from http://mouse.cs.ucla.
edu/mousehapmap/full.html. Each SNP was evaluated individually and
p values were recorded as the strength of the genotype-phenotype associa-
tions. The threshold for genome-wide significance after stringent Bonferroni
correction was 1.25 3 108 (Bland and Altman, 1995). Although a p value of
4.1 3 106 previously has been considered significant for GWA using EMMA
in the hybrid mouse diversity panel (HMDP) (Kang et al., 2008), we considered
this threshold as a suggestive value for associations. The Manhattan plot was
generated using the R package (Turner, 2014).
Gene Array Analysis
See the Supplemental Experimental Procedures.
Western Blotting
Western blotting on mouse and human samples was performed as described
in Vitner et al. (2014) and in the Supplemental Experimental Procedures.
Real-Time PCR
Real-Time PCR was performed as described (Vitner et al., 2014). Primer
sets and conditions are described in the Supplemental Experimental
Procedures.
Statistical Analysis
Comparison between two samples was performed using a two-tailed Stu-
dent’s t test and between multiple groups using one- and two-way ANOVA
followed by the post hoc Turkey’s test. Data were considered statistically sig-
nificant when p < 0.05.
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